DDInter8 DDInter927
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835]
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Abiraterone {u} (Compound) resembles {v} (Compound) Testosterone
Abiraterone {u} (Compound) treats {v} (Disease) prostate cancer
Abiraterone {u} (Compound) binds {v} (Gene) ABCC1
Abiraterone {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Torasemide
Abiraterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Dofetilide
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Abiraterone (Compound) resembles Testosterone (Compound)
Abiraterone (Compound) treats prostate cancer (Disease)
Abiraterone (Compound) binds ABCC1 (Gene)
Abiraterone (Compound) causes Hypokalaemia (Side Effect)
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Torasemide
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Abiraterone may lead to a major life threatening interaction when taken with Dofetilide
Abiraterone may lead to a major life threatening interaction when taken with Ivabradine